Brain on Fire: Ottawa's Vaccine-Injury Program Spent More on Its Contractor Than on the Injured

“My brain is on fire.” It is not a figure of speech. A neurologist who hears those words has a short list of illnesses that can literally do it, and the most infamous of them reads like tabloid copy: anti-NMDA receptor encephalitis, the disease the journalist Susannah Cahalan described in her memoir Brain on Fire: My Month of Madness after her own immune system turned on her neurons. The body builds antibodies against the NMDA receptor, the receptor stops carrying signals, and a healthy person slides into psychosis, seizures, and catatonia inside a few weeks. It is documented, imaged, and named, which is why the phrase lands with anyone who has watched it happen.

So when that same phrase kept surfacing from a witness chair on Parliament Hill this month, the words carried weight. Over four days, September 8 to 11, a group of Canadian lawmakers sat and listened to fifty people describe what happened to their bodies after a COVID-19 shot. The proceeding, chaired by Conservative MP Dean Allison and moderated by the constitutional lawyer Shawn Buckley, was not a government commission. It had no subpoena power and no statutory mandate. It was a citizen inquiry, broadcast live, drawing its fifty witnesses from more than 1,400 applicants screened by doctors for the severity and documentation of their injuries. U.S. Senator Ron Johnson flew up to testify on the first day. Health Canada, invited, did not appear. The agency that ran the rollout would not sit in the room while the people it enrolled explained what the rollout did to them.

Where the money actually went

Start with the arithmetic, because it is not contested and it comes straight from the government’s own books. Canada stood up the Vaccine Injury Support Program in June 2021 with a five-year budget of $111.4 million. By 2026, it had spent $67.6 million, and only $21.7 million of that reached injured claimants. The third-party contractor hired to run the file, Oxaro, was paid $50.6 million, of which roughly $33.7 million went to administrative operations. Set those last two numbers side by side: the program spent more on its contractor’s overhead, $33.7 million, than it paid the injured people it exists for, $21.7 million. Those figures were pried loose not by a reporter but by a parliamentary inquiry from Conservative MP Leslyn Lewis, answered by Health Canada on April 13, 2026.

The throughput is as thin as the spending is heavy. As of late 2022, the program had approved 50 claims out of 1,299 and paid out $2.8 million. Ottawa had once projected about 40 valid claims a year, then quietly revised the expectation to 400, and by this spring the program had received more than 3,300 applications. On April 1, 2026, the whole apparatus was folded into a new Vaccine Impact Assistance Program under the Public Health Agency of Canada, which inherited more than 2,000 open claims and appeals still waiting for an answer. New letterhead, same backlog.

That is the machine the fifty witnesses were describing from the outside. A program that paid its administrator more than its claimants, cleared 50 of its first 1,299 files, and is now run by the same government that would not send one official to hear the testimony. You do not need to resolve the causation debate to see the accountability failure. You need a calculator.

None of this tells you whether a vaccine set any particular witness’s brain alight, and the injured deserve better than to have their suffering oversold to them. The reflexive answer, the one an agency reaches for whenever a vaccine-injured person surfaces, is that temporal association is not causation. That sentence is true. It is also the exact sentence an institution uses when it would rather not fund the study that could settle the question.

The underlying biology is not fringe. A systematic review published this year in Annals of Clinical and Translational Neurology pooled 206 cases of new-onset refractory status epilepticus, or NORSE, the condition in which a previously healthy person starts seizing and does not stop. Seventy-two of them showed the “claustrum sign,” a bilateral inflammation of one of the most densely wired structures in the brain, visible on MRI about seven days after the seizures begin. The patients were young, mean age under 25, and 93 percent ran a fever in the days before their brains lit up. About 74 percent walked away, if they walked away, with chronic epilepsy, and roughly one in eleven died in the hospital. That is what neuroinflammation does to a nervous system in real time, and it is why clinicians increasingly treat brain infection and neuroinflammation as engines of the global epilepsy burden rather than footnotes to it.

NORSE is cryptogenic, the honest medical phrase for “we do not know what set it off,” and nothing in that review implicates a vaccine. It establishes the terrain. The immune system attacking the brain is a described, staged, imaged phenomenon, not an idea a witness invented in front of a camera, and the people who live it reach for the same three words.

The peer-reviewed record already holds what the dismissal waves away. There is a published case of autoimmune encephalitis in a woman five days after her first ChAdOx1 dose, her disability climbing toward total dependence before steroids, immunoglobulin, and rituximab pulled her partway back. There is a documented anti-NMDA receptor encephalitis in a 13-year-old girl after a Pfizer dose, and another after the BNT162b2 shot in an adult. Case reports sit on the lowest rung of the evidence ladder, and the same syndromes follow ordinary infections and tumors. But “we cannot prove causation” and “we chose not to look” are different statements that have been allowed to wear the same coat for four years. Passive reporting systems catch a fraction of real events, and a country that will not put its health agency in a witness chair is not a country running hard at the question.

The medicine, at least, is moving faster than the bureaucracy. At Yale, the COMBAT-NORSE trial plans to enroll 438 patients across 33 hospitals, randomizing eligible cases within the first seven days to one of two immune-suppressing drugs, anakinra or tocilizumab, to learn which one better rescues a brain that has caught fire. Its primary readout is a one-year functional outcome, and results are not yet in. That is the concrete thing to watch, because it treats neuroinflammation as an emergency worth a Phase 3 answer instead of a story to be managed. The other thing to watch is whether the Public Health Agency of Canada, under its new program name, will do what its predecessor would not: sit down and count the neurological injuries honestly. Fifty Canadians testified this month that their bodies had turned on them, and one of them said his brain was on fire. The phrase has a diagnosis behind it. The open question is whether the institution holding the data goes looking, or keeps spending two dollars to run the program for every dollar it hands the injured.

1. The Canada Times – significant share of vaccine-injury program funds spent on administration
2. CBC News – Conservative MP Dean Allison holds independent hearings into COVID-19 vaccine injuries
3. CBC News – $2.8 million paid out so far by Vaccine Injury Support Program
4. Canada.ca – Progress update on the Vaccine Impact Assistance Program
5. Allison Inquiry – covidtestimony.com (witness testimony, Sept 8–11, 2026)
6. Children’s Health Defense – Canadian lawmakers hold inquiry into COVID vaccine injuries
7. Annals of Clinical and Translational Neurology – Burani et al., claustrum involvement in NORSE, systematic review (2026)
8. Epilepsy Currents – “Brain on Fire”: how brain infection and neuroinflammation drive worldwide epilepsy burden (2024)
9. PMC – Autoimmune encephalitis following ChAdOx1 nCoV-19 vaccination (case report)
10. PubMed – Anti-NMDA autoimmune encephalitis post-COVID-19 vaccination in a pediatric patient
11. PMC – Anti-NMDA receptor encephalitis after BNT162b2 COVID-19 vaccination
12. ClinicalTrials.gov – COMBAT-NORSE (NCT07281027), anakinra vs tocilizumab
13. Clinical Imaging – Brain on fire: an imaging-based review of autoimmune encephalitis
14. Issues in Mental Health Nursing – review of Cahalan, “Brain on Fire: My Month of Madness”
15. YouTube – Dr. John Campbell, “My brain is on fire” (Allison Inquiry testimony)